Selinexor reduced surface HLA-E expression on CD5+CD19+ CLL cells in all four patient samples tested, with a mean reduction of 49% at 2000nM after 40 hours in vitro incubation (Figure 2D, p<0.005). The gene discussed is CD5; the disease is B-cell chronic lymphocytic leukemia.